Skip to content
Sleep & circadian healthRandomised trial3 min read

L-arginine 6 g/day for 8 weeks eased everyday fatigue more than placebo in working-age adults

MoveVitals Editorial Collective · Study published · Reading updated

Original paper:Effects of Oral L-Arginine on Everyday Persistent Fatigue, Sleep, and Post-Exercise Lactate Recovery in Community-Dwelling Working-Age Adults: A Double-Blind, Placebo-Controlled Randomized Trial. · Nutrients · 2026 · Original paper ↗

Key takeaway

In a placebo-controlled trial of 120 adults aged 30-59 with persistent fatigue, 6 g/day of L-arginine lowered Fatigue Severity Scale scores more than placebo at 8 weeks (-6.41 vs. -2.23; Holm-adjusted p = 0.024), while 3 g/day did not. Mean scores stayed above the enrollment threshold, so fatigue was reduced, not resolved.

Study design

Randomised trial

Reading basis

Published abstract

Reading focus

Comparator & uncertainty

The research question

Many working adults feel tired every day, and the evidence for nutritional treatments is limited. The authors tested whether the amino acid L-arginine reduces persistent fatigue, and also looked at sleep and how the blood clears lactate after a treadmill run.

Who and how

Randomized, double-blind, placebo-controlled trial of 8 weeks in 120 community-dwelling adults aged 30-59 years with persistent fatigue (Fatigue Severity Scale [FSS] total of 27 or more), given oral L-arginine 3 g/day, 6 g/day or placebo. The primary endpoint was FSS change. Secondary endpoints included the Checklist Individual Strength (CIS), the Pittsburgh Sleep Quality Index (PSQI) and blood lactate during a standardized 30-minute submaximal treadmill run at about 70% VO2max. Data from 119 participants were analyzed with Holm adjustment for multiple comparisons.

What it found

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    At week 8, FSS fell more with 6 g/day than placebo (-6.41 vs. -2.23; Holm-adjusted p = 0.024). The 3 g/day dose did not differ from placebo.
  2. 2
    The CIS improvement with 6 g/day did not survive adjustment for multiple comparisons.
  3. 3
    PSQI sleep scores improved nominally with both doses (3 g/day, p = 0.007; 6 g/day, p = 0.045), the abstract not stating adjusted values for these.
  4. 4
    With 6 g/day, total lactate area under the curve (Holm-adjusted p = 0.041) and lactate at 15 minutes of recovery (Holm-adjusted p = 0.002) were lower than with placebo; resting plasma nitrite did not differ. No serious adverse events occurred.

Limits & uncertainty

  1. 1
    Only 120 adults were enrolled over 8 weeks, so this cannot show longer-term benefit or safety.
  2. 2
    Fatigue was measured with self-rated scales, which can respond to expectation even in a placebo-controlled trial, and mean FSS scores remained above the entry threshold.
  3. 3
    The sleep (PSQI) improvements are nominal rather than corrected for multiple comparisons, and the 3 g/day dose showed no fatigue effect, so the dose pattern is not clean.
  4. 4
    The abstract does not give the funder or confidence intervals; this reading is based on the abstract only.

What to take from it

L-arginine at 6 g/day gave a modest reduction in everyday fatigue over 8 weeks in this trial, not a cure. One trial is not enough to recommend it. Persistent fatigue can have medical causes, and supplements should be discussed with a clinician or pharmacist first.

Reading your own data

If you track sleep and training, note any change in how a standard workout feels and in your sleep duration alongside a weekly fatigue rating on the same scale. Heart rate at a fixed easy pace and recovery heart rate from the same device are more reliable to compare than single sessions. Blood lactate from this trial cannot be measured by a wearable.

How to read this evidence

Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.

Authors’ structured abstract English

The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.

Background/objectives

The evidence for nutritional interventions against fatigue is limited; we evaluated whether L-arginine reduces fatigue in working-age adults.

Methods

In this 8-week randomized, double-blind, placebo-controlled trial, 120 community-dwelling working-age adults aged 30-59 years with persistent fatigue (Fatigue Severity Scale [FSS] total ≥ 27) received oral L-arginine 3 g/day, 6 g/day, or placebo. The primary endpoint was FSS change; secondary endpoints included the Checklist Individual Strength (CIS), Pittsburgh Sleep Quality Index (PSQI), and blood lactate kinetics during a standardized submaximal treadmill run (~70% VO_(2)max, 30 min). Data from 119 participants were analyzed, with Holm adjustment for multiplicity.

Results

At Week 8, FSS decreased more with 6 g/day than with placebo (-6.41 vs. -2.23; Holm-adjusted p = 0.024), whereas 3 g/day did not differ from placebo. The 6 g/day CIS improvement did not survive multiplicity adjustment. PSQI scores improved nominally at both doses (3 g/day, p = 0.007; 6 g/day, p = 0.045). With 6 g/day, the total lactate area under the curve (Holm-adjusted p = 0.041) and 15-min recovery lactate (Holm-adjusted p = 0.002) were lower than with the placebo, whereas the resting plasma nitrite did not differ. No serious adverse events occurred.

Conclusions

L-arginine supplementation at 6 g/day for 8 weeks reduced fatigue severity relative to placebo and was well-tolerated; however, mean FSS scores remained above the enrollment threshold, indicating a reduction in, rather than resolution of, persistent fatigue.

Sources & attribution

Effects of Oral L-Arginine on Everyday Persistent Fatigue, Sleep, and Post-Exercise Lactate Recovery in Community-Dwelling Working-Age Adults: A Double-Blind, Placebo-Controlled Randomized Trial.

Kang EB, Hong SB, Yoon N, Lee N, Kim B.

Nutrients · 2026-10-14

DOI: 10.3390/nu18203375 ↗PubMed · 42942946 ↗Europe PMC · Recorded licence: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

MoveVitals editorial interpretation · educational content · no individual clinical review recorded

Sources checked 2026-11-01

Practical guides

Read in context

·Trial meta-analysis

Exercise improved sleep-quality scores in adults 45 and older with sleep disorders

Pooling 23 randomized trials with 1,478 adults aged 45 to 77 who had sleep disorders, exercise improved Pittsburgh Sleep Quality Index scores (SMD 0.62, 95% CI 0.40–0.83), and aerobic exercise showed the largest effect in the network analysis (SMD 1.34, 95% CrI 0.86–1.82). Certainty was low to moderate, the outcomes were questionnaires, and the best weekly dose of about 539 MET-min/week is a model estimate, not a prescription.

Journal of Exercise Science & Fitness

In-depth explainersRead study →
·Cohort study

Sleep regularity tracked mortality more closely than sleep duration in 60,977 UK adults

Among 60,977 UK Biobank adults who wore a wrist accelerometer for a week, the most regular fifth of sleepers had a fully adjusted all-cause mortality HR of 0.70 (95% CI 0.59–0.83) against the least regular fifth, over about 6.3 years and 1859 deaths. Regularity fitted the data better than sleep duration, but the study is observational and rests on one week of sleep data.

Sleep

In-depth explainersRead study →
·Randomised trial

Sleep extension cut daily energy intake by about 270 kcal in adults with overweight

In 80 adults with overweight who usually slept under 6.5 hours, two weeks of sleep-extension counselling added about 1.2 hours of sleep and lowered measured energy intake by 270.4 kcal/d versus control (95% CI −393.4 to −147.4). The trial was short, single-centre and in a narrow group, so it does not show lasting weight loss or any benefit for people who already sleep enough.

JAMA Internal Medicine

In-depth explainersRead study →
·Cohort study

Six hours or less of sleep at 50 and 60 linked to higher dementia risk

In 7959 British civil servants followed for about 25 years, sleeping six hours or less at age 50 (HR 1.22, 95% CI 1.01–1.48) or age 60 (HR 1.37, 1.10–1.72) was linked to a higher dementia rate than sleeping seven hours, and persistent short sleep gave an HR of 1.30 (1.00–1.69). Sleep was mostly self-reported and the study is observational, so early brain disease or other factors may explain part of the link.

Nature Communications

In-depth explainersRead study →
Sleep & circadian health →